FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:2546-2548 June 16, 2005 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Richardson, P. G. PubMed Citation

Multiple myeloma is a neoplastic plasma-cell dyscrasia that will cause more than 11,000 deaths in 2005 in the United States alone.¹ The usefulness of the many therapies for multiple myeloma is limited, and virtually all patients eventually die from the disease. When thalidomide was shown to be effective against relapsed myeloma in 1999,² more than 30 years had elapsed since a clinical response to any single agent had been reported in at least 25 percent of treated patients.^3,4,5 By the early 2000s, it had become clear that another two agents — lenolidomide⁶ and bortezomib⁷ — had activity against malignant plasma . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Mayo Clinic, Rochester, Minn.

Related Letters:

Bortezomib in Multiple Myeloma
Cecchi M., Caccese E., Messori A., Vandenbroucke J. P., Kroep J. R., Richardson P. G., Boral A. L., Anderson K. C.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1297-1298, Sep 22, 2005. Correspondence

This article has been cited by other articles:

• Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., Pezzoni, G., Allievi, C., Pescalli, N., Cassin, M., di Giovine, S., Nicoli, P., de Feudis, P., Strepponi, I., Roato, I., Ferracini, R., Bussolati, B., Camussi, G., Jones-Bolin, S., Hunter, K., Zhao, H., Neri, A., Palumbo, A., Berkers, C., Ovaa, H., Bernareggi, A., Inghirami, G. (2008). CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood 111: 2765-2775 [Abstract] [Full Text]  
• Reinstein, E., Ciechanover, A. (2006). Narrative review: protein degradation and human diseases: the ubiquitin connection.. ANN INTERN MED 145: 676-684 [Abstract] [Full Text]  
• Buckstein, R., Kerbel, R. S., Shaked, Y., Nayar, R., Foden, C., Turner, R., Lee, C. R., Taylor, D., Zhang, L., Man, S., Baruchel, S., Stempak, D., Bertolini, F., Crump, M. (2006). High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma. Clin. Cancer Res. 12: 5190-5198 [Abstract] [Full Text]  
• Cecchi, M., Caccese, E., Messori, A., Vandenbroucke, J. P., Kroep, J. R., Richardson, P. G., Boral, A. L., Anderson, K. C. (2005). Bortezomib in Multiple Myeloma. NEJM 353: 1297-1298 [Full Text]  
• (2005). Bortezomib for Multiple Myeloma. JWatch General 2005: 8-8 [Full Text]